

Date: 28/05/2014

To
Deputy Manager
Dept. of Corporate Services,
Bombay Stock Exchange Limited
P J Towers, Dalal Street,
Fort, MUMBAI – 400001

Sub: Outcome of Board Meeting held on 28th May 2014-Reg.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 28th May 2014 and transacted following business:

1. Approved the Audited Financial Results for Quarter and year ending on 31st March, 2014

We are herewith attaching the results sheet and Auditor Report on Quarterly Audited Financial Results and year to date Audited Financial Results pursuant Clause 41 of Listing agreement.

2. Considered and approved the appointment of Mr. Hariharan Ravindran as Independent Director of the Company.

We are herewith enclosing brief Profile of. Mr. Hariharan Ravindran.

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

M Kalyan Ram
Whole Time Director

R HARIHARAN Independent Director Profile

1) Educational Qualification

- Master of Commerce
- Chartered Accountant (ICAI)

2) Professional Experience

- Full Time Partner with VNHR & Co since its inception in 2009.
- Employed with Kotak Mahindra Bank Ltd – Hyderabad, from 2007 to 2009 as a Risk Underwriter in the Mortgages Department. was heading operations at Hyderabad. Apart from exercising sanctioning powers, had to engage in team handling as well as training activities within the Bank. Designation at the time of resignation: Senior Manager
- Employed with Aditya Birla Mutual Funds from 2005 to 2007 as Assistant Manger - (Operations).



Vivo Bio Tech Ltd.

Your Drug Discovery Partner

PART - I						
Audited Financial Results for the quarter and Year ended 31/03/2014						
S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED	
		31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
		Audited	Unaudited	Audited	Audited	Audited
1	Income from Operations					
	a) Net Sales/ Income from Operations	405.90	453.24	368.56	1612.55212	1436.57
	b) Other Operating Income	0.00	0.00	0.00	0.00	3.75
	Total Income from operations	405.90	453.24	368.56	1612.55	1440.32
2	Expenses					
	a. Increase/(decrease) in stock in trade and WIP	-26.31	0.00	-2.36	-26.31	-2.36
	b. Consumption of Raw materials	55.02	36.93	0.00	294.97	0.00
	c. Purchase of traded goods	0.00	0.00	373.80		373.80
	d. Employees Cost	36.57	70.37	84.02	222.80	247.22
	e. Depreciation	31.77	42.10	53.50	156.25	157.00
	f. Other Expenditure	0.00				
	1. Administrative Expenditure	301.94	299.05	-38.02	946.14	582.38
	g. Total	399.00	448.45	369.93	1593.86	1358.04
3	Profit/loss from Operations before other income, finance cost and exceptions items(1-2)	6.91	4.79	-1.37	18.70	82.28
4	Other income	29.04	18.00	72.56	88.29	72.56
5	Profit/(loss) from Ordinary activities before finance costs and exceptional items(3+4)	35.95	22.79	71.19	106.99	154.84
6	Finance costs	19.36	11.40	-0.21	39.29	77.64
7	Profit/(loss) from Ordinary activities after finance costs but before exceptional items(5-6)	16.59	11.39	71.40	67.70	77.20
8	Exceptional items	0.00	0.00	0.00	0.00	0.00
9	Profit/Loss from Ordinary Activities before tax(7-8)	16.59	11.39	71.40	67.70	77.20
10	Tax Expense	27.17	3.19	46.02	38.33	53.21
11	Net Profit/Loss from Ordinary Activities after Tax(9-10)	-10.58	8.20	25.38	29.37	23.99
12	Extraordinary Items (Net of Tax expense of Rs.....Lakh)	0.00	0.00	-	-	-
13	Net Profit/Loss for the Period(11-12)	-10.58	8.20	25.38	29.37	23.99
14	Paid Up Share Capital(Face Value of Rs.10/-each)	935.05	935.05	935.05	935.05	935.05
15	Reserves Excluding Revaluation Reserves as per Balance sheet of previous accounting year	-	-	-	-	-
16.i	Earning Per Share(EPS)(Before Extraordinary items)					
	a)Basic	-0.11	0.09	0.27	0.31	0.10
	b)Diluted	-0.11	0.09	0.27	0.31	0.10
16.ii	Earning Per Share(EPS)(After Extraordinary items)					
	a) Basic	-0.11	0.09	0.27	0.31	0.10
	b) Diluted	-0.11	0.09	0.27	0.31	0.10



Registered Office: #608, 6th floor, Lingapur Complex, Himayath Nagar, Hyderabad – 500029, Andhra Pradesh, INDIA; Phone: +91-40-27890662-5; Fax: +91-40-27890669 **Address of Preclinical Research Facility:** Vivo Bio Tech Special Economic Zone, Sy. # 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Andhra Pradesh, INDIA Email: contact@vivobio.com Website: www.vivobio.com

PART -II- Select Information for the Qtr and year ended on 31/03/2014					
A	Particulars of Shareholding				
1	Public Shareholding				
	Number of Shares	2926437	2926437	2926437	2926437
	Percentage of Shareholding	31.30%	31.30%	31.30%	31.30%
2	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	:Number of Shares	0	0	0	0
	:Percentage of Shares				
	(as a % of the total shareholding of promoter and Promoter Group)	0.00	0.00	0.00	0.00
	: Percentage of Shares				
	(as a % of the total sharecapital of the company)	0	0	0	0
	b) Non-Encumbered				
	:Number of Shares	6424083	6424083	6424083	6424083
	:Percentage of Shares				
	(as a % of the total shareholding of promoter and Promoter Group)	100%	100%	100%	100%
	: Percentage of Shares				
	(as a % of the total sharecapital of the company)	68.70%	68.70%	68.70%	68.70%

Notes

- The above results were reviewed by the Audit committee and approved by the Board of Directors in their meeting held on 28th May, 2014 and a limited review of the same has been carried out by the statutory auditors of the company
- Status of complaints from the investors during the quarter ended 31st March, 2014
Pending- 0 Nos Complaints Received -3 Nos., Complaints resolved - 3 Nos., Complaints lying unresolved - 0 No.
- The company Operates in Only one Segment

Place: Hyderabad

Date: 28/05/2014

For VIVO BIO TECH LTD

M.KALYAN RAM
WHOLE TIME DIRECTOR



Vivo Bio Tech Ltd.

Your Drug Discovery Partner

Statement of Assets and Liabilities		In Rupees	
Particulars		As AT 31/03/2014	As at 31/03/2013
		Audited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a) Share Capital	93,505,200	93,505,200
	b) Reserves and Surplus	(8,216,439)	(11,153,271)
	Sub-total -Shareholders' Funds	85,288,761	82,351,929
2	Non-Current Liabilities		
	a)Long Term borrowings	35,459,779	35,856,803
	b) Deffered tax liabilities	14,256,739	11,713,822
	c)Other Long term liabilities	-	-
	d) Long term provisions	1,297,404	1,039,868
	Sub-total -Non-Current Liabilities	51,013,922	48,610,493
3	Current Liabilities		
	a) Short-term Borrowings	30,769,842	-
	b) Trade Payables	85,471,626	87,355,104
	c)Other Curren Liabilities	102,756,377	125,453,786
	d) Short Term provisions	45,147,781	43,003,692
	Sub-total -Current Liabilities	264,145,626	255,812,582
	TOTAL-EQUITY AND LIABILITIES	400,448,309	386,775,004
B	ASSETS		
1	Non-Current Assets		
	a)Fixed Assets		
	i)Tangible Assets	147,930,488	141,451,456
	ii) Intangible Assets	56,720,467	64,590,741
	b) Non-Current investments	1,371,875	1,371,875
	c)Deffered tax assets(net)	-	-
	d) Long term loans and advances	-	-
	e) Other non-current assets	321,955	261,106
	Sub-total Non-Current Assets	206,344,784	207,675,178
2	Current Assets		
	a) Inventories	3,070,509	439,385
	b) Trade Receivables	43,046,510	40,297,967
	c)Cash and cash equivalents	112,359,463	103,056,156
	d) short term loans and advances	31,166,567	29,600,009
	e) Other current assets	4,460,476	5,706,309
	Sub-Total Current Assets	194,103,525	179,099,826
	TOTAL ASSETS	400,448,309	386,775,004



Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad – 500029, Andhra Pradesh, INDIA; Phone: +91-40-27890662-5; Fax: +91-40-27890669 **Address of Preclinical Research Facility:** Vivo Bio Tech Special Economic Zone, Sy. # 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Andhra Pradesh, INDIA Email: contact@vivobio.com Website: www.vivobio.com



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Auditors' Report on Quarterly Financial Results and Year to Date Financial Results of Vivo Bio Tech Limited Pursuant to the Clause 41 of the Listing Agreement

To
The Board of Directors of
Vivo Bio Tech Limited

We have audited the quarterly financial results of **Vivo Bio Tech Limited** ('the Company') for the quarter ended 31st March 2014 and the year to date financial results for the period from 1st April 2013 to 31st March 2014, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, notified under the Companies Act, 1956 read with general circular 8/2014 dated April 4th, 2014 issued by the Ministry of Corporate Affairs and other accounting principles generally accepted in India.


We conducted our audit in accordance with auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:

1. are presented in accordance with the requirements of Clause 41 of the Listing Agreement in this regard; and
2. give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2014, net profit for the year to date results for the period from 1st April 2013 to 31st March 2014.

Further, we also report that we have on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the Company in terms of Clause 35 of the Listing Agreement and found the same to be correct.

For P. Murali & Co.,
Chartered Accountants
FRN: 007257S


A. Krishna Rao
Partner
M. No. 020085



Place : Hyderabad
Date : 28th May 2014